Actually, DHRS9 downregulation has been correlated with poor survival in oral squamous cell carcinoma (19) and colorectal cancer (14) patients, but those who received any anti-cancer therapy were excluded in these two studies. Here, DHRS9 is linked to colorectal cancer.